India’s Glenmark Recalls Wrongly Packaged Oral Contraceptive In U.S.
This article was originally published in PharmAsia News
India’s Glenmark Pharmaceutical recalled seven lots of its generic oral contraceptive from the U.S. market because of a packaging error that obscured the expiration date for the drug.
You may also be interested in...
After issuing Form 483 observations, the FDA has issued a warning letter to Aurobindo’s AuroLife linked to its manufacturing facility in New Jersey. The agency has warned that if the violations are not corrected promptly, it will take further action to ensure quality control.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.